1 Title: Host-Microbe Multiomic Profiling Reveals Age-Dependent COVID-19 2 Immunopathology

3

One sentence summary: We observed age-dependent immune dysregulation at the
 transcriptional, protein and cellular levels, manifesting in an imbalance of inflammatory responses
 over the course of hospitalization, and suggesting potential new therapeutic targets.

7

8 Authors:

- 9 Hoang Van Phan^{1†}, Alexandra Tsitsiklis^{1†}, Cole P. Maguire², Elias K. Haddad³, Patrice M. Becker⁴,
- 10 Seunghee Kim-Schulze⁵, Brian Lee⁵, Jing Chen^{6,7}, Annmarie Hoch⁶, Harry Pickering⁸, Patrick Van
- 11 Zalm⁶, Matthew C. Altman⁹, Alison D. Augustine⁴, Carolyn S. Calfee¹, Steve Bosinger¹⁰, Charles
- 12 Cairns³, Walter Eckalbar¹, Leying Guan¹¹, Naresh Doni Jayavelu⁹, Steven H. Kleinstein¹², Florian
- 13 Krammer⁵, Holden T. Maecker¹³, Al Ozonoff⁶, Bjoern Peters¹⁴, Nadine Rouphael¹⁰, IMPACC
- 14 Network, Ruth R. Montgomery¹², Elaine Reed⁸, Joanna Schaenman⁸, Hanno Steen⁶, Ofer Levy⁶,
- 15 Joann Diray-Arce⁶, *Charles R. Langelier^{1,15}
- 16

17 Affiliations:

- ¹University of California San Francisco
- 19 ²University of Texas Austin
- 20 ³Drexel University/Tower Health Hospital
- ⁴National Institute of Allergy and Infectious Diseases/National Institutes of Health
- 22 ⁵Icahn School of Medicine at Mount Sinai
- ⁶Precision Vaccines Program, Boston Children's Hospital
- ²⁴ ⁷Research Computing, Department of Information Technology, Boston Children's Hospital
- ²⁵ ⁸David Geffen School of Medicine, University of California Los Angeles
- 26 ⁹Benaroya Research Institute
- 27 ¹⁰Emory University
- 28 ¹¹Yale School of Public Health
- 29 ¹²Yale School of Medicine
- 30 ¹³Stanford University
- 31 ¹⁴La Jolla Institute for Immunology
- 32 ¹⁵Chan Zuckerberg Biohub San Francisco
- 33
- ³⁴ [†]These authors contributed equally

35 *Correspondence: <u>chaz.langelier@ucsf.edu</u>

36 **Abstract:**

Age is a major risk factor for severe coronavirus disease-2019 (COVID-19), yet the mechanisms 37 38 responsible for this relationship have remained incompletely understood. To address this, we 39 evaluated the impact of aging on host and viral dynamics in a prospective, multicenter cohort of 1.031 patients hospitalized for COVID-19, ranging from 18 to 96 years of age. We performed 40 41 blood transcriptomics and nasal metatranscriptomics, and measured peripheral blood immune cell populations, inflammatory protein expression, anti-SARS-CoV-2 antibodies, and anti-42 interferon (IFN) autoantibodies. We found that older age correlated with an increased SARS-CoV-43 2 viral load at the time of admission, and with delayed viral clearance over 28 days. This 44 45 contributed to an age-dependent increase in type I IFN gene expression in both the respiratory tract and blood. We also observed age-dependent transcriptional increases in peripheral blood 46 IFN-y, neutrophil degranulation, and Toll like receptor (TLR) signaling pathways, and decreases 47 in T cell receptor (TCR) and B cell receptor signaling pathways. Over time, older adults exhibited 48 49 a remarkably sustained induction of proinflammatory genes (e.g., CXCL6) and serum chemokines (e.g., CXCL9) compared to younger individuals, highlighting a striking age-dependent impairment 50 in inflammation resolution. Augmented inflammatory signaling also involved the upper airway, 51 52 where aging was associated with upregulation of TLR, IL17, type I IFN and IL1 pathways, and 53 downregulation TCR and PD-1 signaling pathways. Metatranscriptomics revealed that the oldest adults exhibited disproportionate reactivation of herpes simplex virus and cytomegalovirus in the 54 upper airway following hospitalization. Mass cytometry demonstrated that aging correlated with 55 reduced naïve T and B cell populations, and increased monocytes and exhausted natural killer 56 cells. Transcriptional and protein biomarkers of disease severity markedly differed with age, with 57 58 the oldest adults exhibiting greater expression of TLR and inflammasome signaling genes, as well as proinflammatory proteins (e.g., IL6, CXCL8), in severe COVID-19 compared to mild/moderate 59 disease. Anti-IFN autoantibody prevalence correlated with both age and disease severity. Taken 60 together, this work profiles both host and microbe in the blood and airway to provide fresh insights 61 into aging-related immune changes in a large cohort of vaccine-naïve COVID-19 patients. We 62 observed age-dependent immune dysregulation at the transcriptional, protein and cellular levels, 63 64 manifesting in an imbalance of inflammatory responses over the course of hospitalization, and 65 suggesting potential new therapeutic targets.

66

67 Main text:

68 Introduction:

Age is a major risk factor for severe Coronavirus disease 2019 (COVID-19), with older adults experiencing markedly greater rates of acute respiratory distress syndrome (ARDS) and death compared to younger indiviudals^{1–3}. Even with vaccination rates above 90%, adults over 75 years of age are 140 times more likely to die if infected with SARS-CoV-2⁴. Despite these striking epidemiological associations, the biological mechanisms underlying the impact of aging on COVID-19 remain incompletely understood.

Observational cohort studies of healthy adults^{5,6} demonstrate that aging leads to baseline 75 increases in plasma concentrations of proinflammatory cytokines^{5,7}, several of which (e.g., IL6) 76 77 are well-known biomarkers of COVID-19 severity, suggesting potential connections between the pathophysiology of human aging and COVID-197. Juxtaposed against this state of aging-78 associated inflammation are functional impairments in innate and adaptive immune signaling, 79 observed during vaccination of aged individuals⁸⁻¹¹. Furthermore, recent human in vitro data 80 81 indicates that aging results in impaired production of type I interferons in monocytes and dendritic cells following Toll-like receptor (TLR) ligation, suggesting disrupted innate immunity^{12–16}. 82

Comparative upper respiratory tract transcriptional profiling has demonstrated that mild SARS-CoV-2 infection induces a more robust innate and adaptive immune response in children compared to adults^{17,18}. Paradoxically, amongst adults hospitalized for COVID-19, a more robust immune response underlies the pathogenesis of severe disease, suggesting more complicated relationships between aging and host defense for older individuals. Adding further complexity, and highlighting the need for additional investigation, is the association between increased age, development of anti-interferon autoantibodies (autoAbs), and disease severity^{2,19,20}.

The pathophysiology of COVID-19 involves a dynamic relationship between SARS-CoV 2 and the host immune response^{21,22}, yet studies of COVID-19 and aging have assessed each
 independently. Furthermore, heterogeneity in human physiology necessitates a large sample size

to optimally study aging and host immunity. To address these gaps, we leverage data from 1,031
adults hospitalized for COVID-19 enrolled in the IMPACC (IMmunoPhenotyping Assessment in a
COVID-19 Cohort) cohort^{2,23}, and perform a multiomic, host/microbe systems immunoprofiling
study of aging.

From 2.523 longitudinally collected blood and nasal swab samples, we investigate the 97 impact of aging on SARS-CoV-2 viral load, SARS-CoV-2 antibody (Ab) levels, host gene 98 expression, inflammatory protein expression, immune cell populations, and the nasal microbiome. 99 Our study leverages a robust multicenter cohort to gain new insights into aging and immunity by 100 101 integrating host and microbe data. This work builds on landmark clinical studies demonstrating that age is a major risk factor for COVID-19 severity¹⁻³, assesses the generalizability of early 102 translational studies that included smaller numbers of study participants^{7,12,24,25}, and generates 103 104 fresh insights into age-dependent COVID-19 pathophysiology that could assist in developing age-105 specific therapeutic interventions and biomarkers of disease severity.

106

107 **Results:**

108 Study cohort

109 We analyzed blood and nasal swab specimens from 1.031 adults with COVID-19 enrolled in the IMPACC cohort from 20 hospitals across the United States^{2,23} (Fig. 1, Supp. Table 1). 110 Participants were grouped into quintiles based on age for analyses (18-46, 47-54, 55-62, 63-70, 111 and 71-96 years old), ranging from 187 to 223 participants (median 206 participants) per age 112 113 group (Fig. 2a). We analyzed age distributions across five previously defined COVID-19 disease trajectory groups², ranging from mild disease with brief length of hospital stay (TG1) to severe 114 disease and death (TG5). We found that advanced age was significantly associated with disease 115 116 trajectory group (Fig. 2b) and mortality (Fig. 2c). To investigate host immunologic and microbial features associated with age, we employed a wide range of assays at baseline (within 72 hours 117 of hospital admission) and longitudinally post-hospital admission (Fig. 1, Methods). These 118

- included transcriptional profiling of PBMCs and nasal swabs, soluble serum immune protein
- 120 profiling, whole blood mass cytometry (CyTOF), nasal metatranscriptomics, SARS-CoV-2 IgG
- 121 assays, and anti-IFN- α autoAb measurements.

122



123

Fig. 1: Graphical study overview. This study evaluated 1,031 COVID-19 patients between the ages of 18 and 96 enrolled in the IMPACC cohort at 20 hospitals across the United States. Blood (PBMCs, plasma and serum) and nasal swab samples were collected at up to 6 visits over 28 days and processed for RNA sequencing, proteomics, mass cytometry, and serology.

- 128
- 129

9 Aging is associated with higher SARS-CoV-2 viral load, impaired viral clearance, and lower

130 SARS-CoV-2 antibody levels

Older adults had a significantly higher SARS-CoV-2 viral load at Visit 1, measured in reads per million (rpM) from nasal swab RNA sequencing (P = 0.0011, Fig. 2d), a measurement that highly correlated with qPCR cycle threshold (P < 2.2e-16, Supp. Fig. 1). This age-related increase in viral load was not explained by differences in time from symptom onset (Supp. Fig. 2). Longitudinal analysis also revealed significant differences in viral load dynamics, with the oldest adults demonstrating reduced viral clearance compared to the youngest adults (P = 0.0024, Fig.

137 2e). We also assessed anti-SARS-CoV-2 receptor binding domain (RBD) IgG levels across the

five age groups, and found that the oldest adults had lower levels at Visit 1 (Supp. Fig. 3a) and







Fig. 2: Older adults have more severe COVID-19 and higher SARS-CoV-2 viral loads. (a) Age distribution of the participant cohort. (b, c) Box plot showing the relationship between patients' age and (b) trajectory group severity or (c) mortality. (d) Nasal swab SARS-CoV-2 viral load at Visit 1 (reads per million (rpM) measured by metatranscriptomics) in each age group. In (b-d), P-values were calculated using Kruskal-Wallis test. (e) Nasal swab SARS-CoV-2 viral load over time in each age group. P-value was calculated with generalized additive mixed effects modeling.

6

148 Age-dependent differences in immune cell populations

We quantified differences in proportions of immune cell populations in the peripheral blood 149 by mass cytometry (CyTOF) to assess whether aging altered cell frequencies²³. Using a panel of 150 43 Abs designed to identify cell lineages in whole blood samples from Visit 1, we found 21 cell 151 types (Fig. 3a) significantly associated with participant age (adjusted P < 0.05, Fig. 3b). Increased 152 age correlated with higher proportions of circulating classical monocytes (CD14+ CD16-), non-153 classical monocytes (CD14- CD16+), and intermediate monocytes (CD14+ CD16+). Terminally 154 differentiated/exhausted natural killer (NK) cell (CD56^{low} CD16^{hi} CD57^{hi}) proportions also 155 156 increased with age, as did activated CD4+ T cells and central memory (CM) CD8+ T cells (Fig. 157 3b, c). In contrast, older adults had lower proportions of naïve CD8+ T cells, naïve B cells, gammadelta ($\gamma\delta$) T cells, and plasmablasts (Fig. 3c). Finally, we found that the age-related differences in 158 159 cell type frequencies were not affected by SARS-CoV-2 viral load (Supp. Fig. 4).



160

Fig. 3: Aging alters immune cell populations during COVID-19. (a) Uniform Manifold Approximation and Projection (UMAP) plot highlighting blood cell types analyzed by CyTOF. (b) Bar plot depicting blood cell types that are upregulated (red) or downregulated (blue) with age at Visit 1. "gd T cell" stands for $\gamma\delta$ T cell. (c) Scatter plots depict centered log ratio (CLR) transformed proportions of CD14+CD16+ monocytes and naïve CD8 T cells as a function of age. P values were calculated using linear modeling with Benjamini-Hochberg correction.

166

167 Age-dependent changes in PBMC gene expression at the time of hospitalization

Next, we performed PBMC transcriptional profiling and identified 3,763 genes significantly
 associated with age at baseline (Visit 1), controlling for sex and disease severity (see Methods)
 (adjusted P < 0.05, Fig. 4a). Gene set enrichment analysis (GSEA) revealed upregulation of

several innate immune-related pathways in older participants, including IFN- α/β and TLR cascades, as well as IFN- γ signaling (Fig. 4b). In contrast, several adaptive immunity-related pathways were downregulated in older individuals, such as B cell receptor (BCR) signaling, T cell receptor (TCR) signaling, and PD1 signaling.

175

176 Increased activation of type I interferon signaling in older adults

Prior studies have demonstrated a direct relationship between SARS-CoV-2 viral load and 177 IFN-stimulated gene (ISG) expression^{17,26}. We therefore hypothesized that the strong positive 178 179 correlation between age and viral load (Fig. 2e) might contribute to the upregulation of innate immunity genes and pathways that we observed in older adults. To test this hypothesis, we 180 repeated the differential expression and GSEA analyses while controlling for SARS-CoV-2 viral 181 load. Age-related increases in IFN-γ, TLR signaling, and neutrophil degranulation remained 182 significant. IFN- α/β , IL2, and caspase activation signaling, however, lost statistical significance. 183 suggesting that the stronger activation of these pathways in older patients was due to the age-184 related increase in viral load. 185

To assess whether our observations were specific for COVID-19 or reflected general effects of aging, we compared our GSEA results against public data from 14,983 healthy adults across the age spectrum⁵. While we observed age-related upregulation of some pathways (e.g., IFN- γ and TLR signaling) in both our data and the healthy controls (Supp. Fig. 5a), other pathways were uniquely upregulated in the context of COVID-19 (e.g., caspase activation, TRAF6-mediated IRF7 activation) (Supp. Data 3). Similarly, age-related downregulation of TCR and BCR signaling, as well as several other pathways, was unique to COVID-19 (Supp. Fig. 5b).

193

194 Age-dependent differences in the longitudinal dynamics of PBMC gene expression

We next performed a longitudinal analysis of PBMC transcriptomics data over 28 days 195 196 following hospital admission to identify genes that exhibited age-dependent differences in temporal dynamics, while controlling for participants' sex and severity trajectory group. Using 197 linear mixed effects modeling, we identified 2,737 genes that had different longitudinal dynamics 198 across age guintiles (Fig. 4c, Supp. Data 5). Several groups of genes demonstrated marked 199 differences in expression dynamics. For example, the expression of MHC class II genes (e.g., 200 HLA-DRA) increased over time post-hospitalization in all age groups, but the rate of increase was 201 areater in younger participants (Fig. 4d, e. Supp. Fig. 6). In contrast, the expression of MHC class 202 203 I genes (e.g., HLA-A) decreased over time across all five age groups, but the rate of decrease 204 was greater in older participants. TCR signaling genes (e.g., CD3E, LAT) were globally upregulated over time, however their induction was notably attenuated in the oldest versus 205 206 youngest age quintiles.

The longitudinal dynamics of several canonical inflammatory genes also differed between age groups. For instance, the expression of *CXCL6* increased over the course of hospitalization in the oldest age group, while in younger participants its expression decreased markedly. In contrast, expression of the anti-inflammatory gene *IL10RA* in the youngest participants increased over time to a much greater extent compared to the oldest participants, suggesting both greater activation and impaired attenuation of immune signaling with advanced age.



214 Fig. 4: Aging leads to changes in PBMC gene expression during COVID-19. (a) Volcano plot highlighting genes 215 associated with age at Visit 1 in PBMC RNA-seg data. (b) Plot demonstrating the normalized enrichment score of select 216 Reactome pathways associated with age at Visit 1, with and without controlling for viral load, in PBMC samples. (Full 217 results are tabulated in Supp. Data 1 and 2.) P values in (a, b) were calculated with limma's linear model and Benjamini-218 Hochberg correction. (c) Heatmap representing the temporal slopes (i.e., change in gene expression per 1 day) of 219 2,812 genes that differ longitudinally between the 5 age groups (adjusted P < 0.05). (d) Heatmaps representing the 220 temporal slopes of select MHC, inflammatory, and TCR signaling genes from (c). (e) Plots demonstrating the temporal 221 dynamics of 6 example genes from (g). P values were calculated using linear mixed effects modeling and Benjamini-222 Hochberg correction. (Full temporal dynamics plots with confidence intervals are provided in Supp. Fig. 6.)

223

Age-dependent differences in cytokine and chemokine levels upon hospitalization and

225 over time

The impact of aging on immune signaling in COVID-19 was also evident at the protein 226 level. Analysis of proximity extension assay (Olink) protein data from serum samples identified 43 227 228 proteins that significantly correlated with age at the time of hospital admission (Fig. 5a, b, Supp. 229 Fig. 7a). Of these, 31 increased with age, and the protein with the greatest effect size was CXCL9, a T-cell chemoattractant induced by IFN- γ and produced by neutrophils and macrophages⁶. 230 Twelve proteins significantly decreased with age, including TNFSF11, which is involved in the 231 232 regulation of T cell-dependent immune responses and group 2 innate lymphoid cell-mediated type 2 immunity²⁷, and SIRT2, which may attenuate aging-associated inflammation through de-233 234 acetylation of the NLRP3 inflammasome²⁸.

Based on prior work¹⁷, we hypothesized that aging might affect the relationship between protein expression and viral load. Consistent with this idea, we identified eight cytokines and chemokines whose expression levels correlated with SARS-CoV-2 viral load (Fig. 5c), and observed differences in this relationship between the oldest and youngest age groups. For instance, expression of IL10, a key anti-inflammatory cytokine, increased more strongly in

12

younger versus older adults in response to viral load. CX3CL1, a chemoattractant of T cells and
 monocytes, exhibited a similar relationship (Fig. 5c).

We next evaluated the longitudinal dynamics of cytokine/chemokine expression in the serum after hospitalization (Fig. 5d). The expression of several cytokines, such as TNFSF11, increased steeply over time in younger adults but lagged in the oldest adults (Fig. 5e, Supp. Fig. 7b). Conversely, the expression of several proinflammatory cytokines and chemokines such as CXCL8, CXCL9 and IL6 decreased rapidly over time in younger adults, while in the oldest adults expression increased over time (CXCL8, CXCL9) or declined more slowly (IL6) (Fig. 5e).

248



Fig. 5: Aging leads to differences in cytokine and chemokine levels during COVID-19. (a) Bar plot highlighting proteins that are upregulated (red) or downregulated (blue) with age at Visit 1 (adjusted P < 0.05). (b) Scatter plots of the normalized protein expression (NPX) of representative proteins, CXCL9 and SIRT2, as a function of age. P values

are calculated using linear regression and Benjamini-Hochberg correction. (c) Dot plot representing the slope of cytokine expression versus viral load in the youngest and oldest age quintiles, [18,46] and [71,96], respectively. (d) Heatmap depicting temporal slopes (i.e., change in protein expression per 1 day) of all cytokines that display agedependent longitudinal dynamics (adjusted P < 0.05). (e) Plots showing the temporal dynamics of 4 example cytokines from (d). P values in (d, e) are calculated using linear mixed effects modeling and Benjamini-Hochberg correction.

258 259

Age-dependent changes in respiratory tract gene expression and the airway microbiome

260 We next asked whether aging was associated with changes in host gene expression and the upper airway microbiome (including virome) using nasal swab metatranscriptomics. We 261 identified 913 host genes that were significantly associated with age (Fig. 6a), representing 262 several key immune signaling pathways (Fig. 6b). TLR signaling, which plays an important role in 263 microbial recognition, was upregulated with age, as were genes related to IFN- α/β , IL1, IL4, IL13, 264 265 IL10, IL17, and caspase activation signaling. In contrast, T cell-related pathways (TCR signaling, 266 co-stimulation by the CD28 family, and PD1 signaling) were downregulated with age, similar to 267 our observations in peripheral blood. In silico prediction of upstream cytokine activation states demonstrated age-related activation of TNF, IL6, IFN-γ, IL1A/B, IL22 and CSF1 (Fig. 6c). 268

Our study design enabled assessment of inflammatory pathways across anatomic compartments. Thus, we were interested in the extent to which gene expression in the blood and the upper respiratory tract was coordinated. To this end, we calculated the Pearson's correlation coefficients of gene expression between matched PBMC and nasal samples in the youngest group, and separately in the oldest group. We found 52 genes that had relatively high correlation coefficients in both groups, in particular those related to type I IFN signaling (e.g., *IFI6, IFI44, IFIT3*) and antigen presentation (HLA genes) (Fig. 6d).

As TLR pathways in the airway were strongly upregulated with age, we asked whether this could be due to differences in SARS-CoV-2 viral load and/or the nasal microbiome. We found that at Visit 1, the total bacterial load correlated with both ISG and TLR gene expression, while SARS-CoV-2 viral load only correlated with ISG expression (Fig. 6e). We thus considered whether

variations in bacterial load across the age span might explain the observed age-related TLR
 signaling differences, however no variation was found (Supp. Fig. 8).

We also considered whether age-related differences in specific taxa within the airway 282 283 microbiome might contribute to the aforementioned differences in TLR signaling. Metatranscriptomic analysis identified only one significant genus, Lawsonella, whose abundance 284 decreased with age (Fig. 6f). Lawsonella abundance positively correlated with TLR gene 285 expression across all age groups, however, demonstrating that it did not account for the age-286 related upregulation in TLR signaling (Fig. 6g). Lastly, we evaluated the upper respiratory tract 287 288 virome, and observed reactivation of herpes simplex virus and cytomegalovirus over the course 289 of hospitalization in the oldest age guintile, but not in younger participants (Fig. 6h). This suggested that older adults may have less capacity to maintain innate immune control of latent 290 viral infections. 291



Fig. 6: Aging changes upper respiratory tract gene expression and the airway microbiome in COVID-19. (a) Volcano plot depicting genes associated with age at Visit 1 in nasal swab metatranscriptomics data. (b) Normalized enrichment scores of select Reactome pathways associated with age at Visit 1, with (right) and without (left) controlling for viral load, in nasal samples. (c) Bar plot depicting cytokines predicted by Ingenuity Pathway Analysis to be upregulated with age in nasal samples. (d) Scatter plot depicting the Pearson's correlation coefficient of gene 16

298 expression between PBMC and nasal samples. Each dot indicates the correlation coefficient between PBMC 299 expression and nasal expression of a gene, in the youngest (x-axis) and oldest (y-axis) age group. The black dots mark 300 the genes with correlation coefficients > 0.5 in both age groups (n = 52 genes). (e) Dot plot highlighting correlations 301 between SARS-CoV-2 viral load (log-transformed reads per million (rpM)), total bacterial abundance (log-transformed 302 rpM), interferon stimulated gene (ISG) expression score and Toll like receptor (TLR) gene expression score. (f) Relative 303 abundance of Lawsonella (rpM) across the age quintiles. In (f, g), P values were calculated with one-way ANOVA test. 304 (g) Correlation between Lawsonella relative abundance and TLR gene expression across the age quintiles. P values 305 were calculated using the test of association with Pearson's correlation coefficient and adjusted with Benjamini-306 Hochberg correction. (h) Percentages of cases with herpes simplex virus (HSV) or cytomegalovirus (CMV) transcript 307 detection in the youngest versus oldest age quintiles. The number on top of each bar indicates the number of positive 308 cases over the number of total samples. P-values were calculated by Fisher exact test.

309

310 Relationships between aging, immune response, and COVID-19 severity

Previous studies have established that severe COVID-19 involves a dysregulated host response characterized by inappropriate activation of inflammatory and immunoregulatory pathways^{29–31}. We therefore sought to examine the intersection of aging, COVID-19 severity, and host immune responses by assessing PBMC gene expression differences at Visit 1 between participants with mild/moderate (baseline respiratory severity ordinal scale² (OS) 3-4) and severe (baseline OS 5-6) COVID-19, within the youngest and oldest age groups (Fig. 7a).

317 Several immune signaling pathways were associated with disease severity in an age-318 dependent manner. For example, only in the oldest age quintile was severe COVID-19 associated with upregulation of IL3, IL5 and GM-CSF, IL4 and IL13, TLR, and NRLP3 inflammasome 319 320 signaling pathways in the upper airway. Similarly in the blood, we found that the IL1 signaling pathway was only upregulated in severe COVID-19 in the oldest adults. We also identified several 321 322 pathways that associated with COVID-19 severity independent of age. For example, in PBMCs from both the youngest and oldest participants, severe disease was associated with upregulation 323 of neutrophil degranulation genes, and downregulation of pathways related to TCR, IFN- α/β , IFN-324 γ , IL2 and PD1 signaling. 325

326 Assessment at the protein level provided further insights regarding the immunological 327 intersection of aging and COVID-19 severity (Fig. 7b). Notably, we found that the expression of several canonical proinflammatory cytokines and chemokines, such as IL6, oncostatin M (OSM), 328 329 CXCL8 and CXCL9, was uniquely upregulated with disease severity in the oldest adults. Increased expression of the anti-inflammatory cytokines TGF- $\beta 1$ and IL10 in severe disease was 330 also specific to the oldest age quintile. Serum concentrations of several other proteins increased 331 332 in severe disease independent of age, including CCL7, a leukocyte chemoattractant³², S100A12, a neutrophil-derived cytosolic pro-inflammatory protein³³, and CD274 (PDL1), an immune 333 checkpoint inhibitor. Similarly, we found that severity was associated with reduced expression of 334 335 several cytokines regardless of age, including IL12B and LTA (TNF- β). We tested whether the differences in SARS-CoV-2 viral load could significantly influence the results, and found that they 336 did not (Supp. Fig. 9). 337

Finally, we asked whether anti-IFN- α autoAb prevalence was associated with aging and COVID-19 severity. We found a significant positive correlation between age and anti-IFN- α autoAb prevalence at Visit 1 (Fig. 7c), and a greater prevalence of the autoAbs in participants with severe disease (Fig. 7d). The presence of anti-IFN- α autoAbs was also associated with impaired ISG expression (Supp. Fig. 10).



344 Fig. 7: Aging and COVID-19 severity. (a, b) Dot plots highlighting a) select Reactome pathways in PBMC or nasal 345 RNA-seq data, and b) serum proteins (Olink) that were upregulated in severe participants (baseline respiratory severity 346 ordinal scale 5-6) compared to mild/moderate (ordinal scale 3-4) participants at Visit 1, stratified by age group (youngest 347 or oldest). P values in (a, b) were calculated with linear modeling and Benjamini-Hochberg correction. (c) Box plot 348 demonstrating association between age and presence of anti-IFN- α autoAbs in the 835 participants with available 349 autoAb data at Visit 1. P value was calculated with the Wilcoxon rank-sum test. (d) Bar plot demonstrating the 350 percentage of severe and mild/moderate participants who had anti-IFN-α antibodies (9/542 participants, 1.66% in 351 mild/moderate; 20/293 participants, 6.83% in severe). P-value was calculated using the Chi-squared test.

352

353 Integrated analysis of protein and transcriptomics data

Finally, we sought to integrate findings across genes and proteins, and between the blood 354 355 and airway compartments. Integrated network analysis of statistically significant age-associated 356 proteins and age-associated genes from the blood identified three prominent nodes related to chemokine ligand (CCL) signaling, T cell signaling and the cell cycle (Fig. 8a, see Methods). 357 Additionally, analysis of the ten most significant proteins and their immediately downstream genes 358 359 illuminated the complex cross talk between several key immune mediators. For example, CXCL9 activates the genes CXCR3 and CXCR5, and inhibits the gene DPP4 (also known as CD26), 360 which is upregulated on T cells after activation³⁴ (Supp. Fig. 11). Of these, CXCL9 was positively 361 362 associated with age, while the three downstream genes were negatively correlated with age.

363 To investigate how aging could potentially affect ligand-receptor interactions in both the blood and airway, we studied ligands in our protein data that were significantly associated with 364 age at Visit 1, and examined the expression of the genes that encoded their cognate receptors. 365 366 This analysis further highlighted transcriptomic/proteomic concordance and discordance (Fig. 8b). 367 For example, aging was associated with increased expression of serum CXCL9 and CCL11, but decreased expression of *DPP4*, which encodes a receptor for these ligands. In contrast, the 368 expression of both TNF ligand and its receptors (e.g., TNFRSF1A, TNFRSF1B, LTBR) were 369 positively associated with age. 370



Fig. 8: Integrated network analysis of serum cytokine/chemokine and PBMC and nasal transcriptomic data. (a)
Network analysis of serum cytokines and PBMC genes significantly associated with age at Visit 1 using protein-protein
interactions reported in Omnipath. (b) Analysis of ligand-receptor interactions from cytokine data, PBMC and nasal
RNA-seq data. The inner most ring shows the significant cytokines from Visit 1 analysis and their magnitude of their
average change per 1 year of age. The two outer rings illustrated genes that encode known receptors for each cytokine
and their associated change per one year of age. P values for the cytokines were calculated using linear models and
Benjamini-Hochberg correction. *P<0.05, **P<0.01, ***P<0.001.

380

381 Discussion:

An effective host response to viral infection depends on potent early innate immune 382 activation, engagement of adaptive immune effectors, and then, upon effective viral clearance, 383 attenuation of this inflammatory signaling to prevent excessive tissue and pathologic 384 consequences³⁵. We observed age-dependent dysregulation of this program at the 385 transcriptional, protein and cellular levels, manifesting in an imbalance of inflammatory responses 386 over the course of hospitalization. Our results identify discrete innate and adaptive immune 387 388 signaling pathways which are altered with age, suggesting potential targets for therapeutic 389 intervention.

The role of type I IFN signaling in age-related immune dysregulation during COVID-19 has remained unclear, with some reports suggesting impaired induction of ISGs^{7,15,24} and others demonstrating the contrary^{12,25}. We found that older age was associated with increased type I IFN signaling in both the blood and respiratory tract, but that the relationship was principally driven by differences in SARS-CoV-2 viral load. In contrast, IFN- γ signaling, which is associated with poor prognosis in COVID-19 participants³⁶, was significantly upregulated with age independent of viral load.

397 Several factors likely contribute to higher SARS-CoV-2 viral loads in older adults, including 398 impaired T and B cell immunity and impaired MHC antigen presentation, each of which we 399 observed at the transcriptional, protein and cellular levels in our dataset. Delayed viral clearance due to these age-related factors could facilitate the evolution of novel SARS-CoV-2 variants^{37,38}. 400 401 Therefore, it is possible that coronavirus evolution could occur inside the host to a greater extent 402 in older adults compared to the young, although our study was not designed to test this possibility. Older adults had lower proportions of naïve CD8+ T cells and $\gamma\delta$ T cells, which contribute 403 to effective clearance of viral pathogens^{24,39,40}. Terminally differentiated/exhausted NK cells, 404 which are associated with severe COVID-19⁴¹, were more prevalent in older adults, as previously 405

observed¹², as were central memory CD8+ T cells. Impaired T cell signaling in older adults was
also observed at the transcriptional level in both the blood and the upper respiratory tract upon
hospitalization. Longitudinal analyses demonstrated attenuated expression dynamics of TCR
signaling-related genes in the older participants' blood samples (Fig. 3g, h). We also observed
differences in the relationship between viral load and cytokines important for T cell recruitment in
the oldest versus youngest adults, such as the chemokine CX3CL1.

Younger adults exhibited a much more robust induction of MHC II gene expression over the course of hospitalization. This is consistent with a previous study that reported *HLA-DR* expression increases over time following symptom onset in young COVID-19 participants, but not in older ones¹². We also found that expression of MHC I genes decreased more rapidly posthospitalization in the oldest versus the youngest adults. Given that SARS-CoV-2 can subvert immune responses by reducing MHC I surface levels in infected cells⁴², our results suggest that older participants may be even more vulnerable to this viral immune evasion mechanism.

Evidence of impaired B cell immunity was also observed in the older participants, consistent with prior studies^{12,24}. Age was associated with reduced expression of genes involved in BCR signaling at the time of hospitalization. Furthermore, we observed lower proportions of naïve B cells and plasmablasts in the oldest adults. Functional ramifications of this were evident in decreased anti-SARS-CoV-2 RBD Ab levels, both upon hospitalization and when assessed longitudinally over 28 days.

Effective modulation of inflammatory responses is critical for restoration of immune homeostasis and mitigation of excessive tissue damage. We found consistent evidence of prolonged, potentially pathologic inflammatory responses in the oldest adults from transcriptomic and proteomic analyses. For instance, upon hospitalization, proinflammatory cytokines such as TNF, IL6, CXCL8, and CXCL9 were higher in the older participants, and continued to increase over time. In contrast, these cytokines decreased over time in the younger participants. Our results suggest that age-related changes may exacerbate the overexuberant inflammatory

432 signaling in severe COVID-19, an early hypothesis^{12,24} that has not yet been validated in a large
433 observational cohort.

The oldest adults in our cohort had evidence of HSV and CMV reactivation in the airway over the first 28 days after hospitalization. This may reflect impaired antiviral immune defenses in older adults exacerbated in the context of SARS-CoV-2 challenge. Furthermore, reactivation of latent Herpesviridae may contribute to excessive inflammatory responses observed in the older adults, as has been described in participants with human immunodeficiency virus (HIV) infection⁴³.

Advanced age was also associated with upregulation of TLR signaling genes in both the airway and the blood, independent of SARS-CoV-2 viral load (Fig. 3e, 5b). We found that airway bacterial load correlated with TLR expression independent of age, and compositional differences in the microbiome across age groups did not explain this association, suggesting that age-related increases in TLR gene expression were caused by microbe-independent factors. Consistent with this idea are studies demonstrating that upregulation of innate immune receptors, including TLRs, could be an intrinsic feature of inflammaging^{24,44}.

Severe COVID-19 is characterized by dysregulated, pathologic inflammatory 447 responses^{29,45,46}. We found that aging was associated with higher expression of several signaling 448 pathways previously implicated in this pathologic immune dysregulation. For instance, in the 449 oldest adults, severe COVID-19 was uniquely associated with impaired systemic Type 1 T helper 450 cell (IL2, GM-CSF) and Type 2 T helper cell (IL5) responses, juxtaposed against hyperactivation 451 of proinflammatory cytokines such as IL6, OSM, CXCL8, and CXCL9. In the airway, severe 452 453 COVID-19 in the oldest age group led to greater NLRP3 inflammasome and TLR activation compared to the youngest group. These differences raise the possibility that older adults with 454 455 severe COVID-19 may respond differently, and perhaps more favorably, to immunomodulatory therapies directed at certain inflammatory cytokines. 456

We also found that many features of severity-associated immune dysregulation were conserved across the lifespan, including an impairment in type I IFN signaling in severe disease. While presence of anti-IFN- α autoAbs was associated with impaired ISG expression and increased COVID-19 severity, they were detected in < 7% of adults in the oldest age quintile, suggesting a potentially important, but overall limited contribution to aging-associated COVID-19 severity relative to other immunological factors.

Our study is the largest molecular assessment of aging and COVID-19 to date (n = 1,031463 participants at 20 hospitals across the United States), and one of the few to perform an integrated 464 assessment of both immune and microbial features, allowing for identification of aging-related 465 466 changes at a scale not previously achieved. We conducted multiomic, host/microbe systems immunoprofiling to assess the longitudinal dynamics of immune responses at the cellular, 467 transcriptional and protein level in both the blood and airway. In addition, we add to the COVID-468 469 19 aging literature by integrating immunological analyses with assessment of both viral and microbiome dynamics over the course of hospitalization. 470

Our findings may have implications for age-specific COVID-19 therapeutic approaches. For example, a longer duration of antiviral therapy in older adults may be needed to achieve sufficient viral clearance for infection resolution compared to younger participants, and immunotherapy regimens may be particularly beneficial in older age, given impaired B cell responses. In addition, the optimal timing and use of immunomodulatory therapies (such as corticosteroids) may differ across the age spectrum, given the need to maximize control of inflammation without compromising the immune response to infection^{47,48}.

Limitations of our study include the lack of a concurrently enrolled SARS-CoV-2-negative control group, and the lack of a non-hospitalized COVID-19 group. To partially address the first limitation, we analyzed publicly available gene expression datasets to incorporate findings from unrelated, healthy cohorts⁵. Participants in our current study were enrolled prior to the introduction of SARS-CoV-2 vaccines, and age-related differences in host immune responses may differ from

a contemporary cohort due to variation in both vaccination status and the circulating SARS-CoV2 variants. While this aspect limits extrapolation of our findings to immunized older adults, the
naïve state of our study population was also a strength, as our results are not confounded by prior
vaccination or infection, providing a window into age-related differences in immune response to
a novel emerging viral respiratory pathogen.
In summary, we find that aging has marked impacts on host immune and viral dynamics

in both recognized and novel ways in hospitalized participants with COVID-19. Notably, older

490 adults exhibited impaired viral clearance, dysregulated immune signaling, and persistent and

491 presumably pathologic activation of proinflammatory genes and cytokines.

492 **Materials and methods**:

493 **Patient enrollment and sample collection**

This study leveraged data from the IMPACC cohort^{2,23}, which enrolled participants from 494 495 20 hospitals across 15 medical centers in the United States between May 5th, 2020 and March 19th, 2021. Eligible participants were participants hospitalized with SARS-CoV-2 infection 496 confirmed by RT-PCR and symptoms or signs consistent with COVID-19. The detailed study 497 design and schedule for clinical data and biologic sample collection, and shared core platform 498 assessments were previously described^{23,30}. Detailed clinical assessments and sampling of blood 499 500 and upper respiratory tract were performed within approximately 72 hours of hospitalization (Visit 1), and on approximately Days 4, 7, 14, 21, 28 after hospital admission. As previously described²³. 501 biological sample collection and processing followed a standard protocol utilized by every 502 503 participating academic institution.

504

505 Ethics

NIAID staff conferred with the Department of Health and Human Services Office for 506 Human Research Protections (OHRP) regarding potential applicability of the public health 507 surveillance exception [45CFR46.102(I)(2)] to the IMPACC study protocol. OHRP concurred that 508 the study satisfied criteria for the public health surveillance exception, and the IMPACC study 509 team sent the study protocol, and participant information sheet for review, and assessment to 510 institutional review boards (IRBs) at participating institutions. Twelve institutions elected to 511 512 conduct the study as public health surveillance, while three sites with prior IRB-approved biobanking protocols elected to integrate and conduct IMPACC under their institutional protocols 513 (University of Texas at Austin, IRB 2020-04-0117: University of California San Francisco, IRB 20-514 515 30497; Case Western reserve university, IRB STUDY20200573) with informed consent requirements. Participants enrolled under the public health surveillance exclusion were provided 516 information sheets describing the study, samples to be collected, and plans for data de-517

518 identification, and use. Those that requested not to participate after reviewing the information 519 sheet were not enrolled. In addition, participants did not receive compensation for study 520 participation while inpatient, and subsequently were offered compensation during outpatient 521 follow-ups.

522

523 **Common statistical analyses framework**

All raw data was obtained from the IMPACC study and are publicly available^{2,23}. QC was 524 performed by the IMPACC study as previously reported^{2,23}. All data analyses were done in R 525 526 v4.0.2. For each data type, we investigated the behavior of features both at Visit 1 (within 72 527 hours of hospital admission for most of the participants) and longitudinally for scheduled visits (Visits 1-6, up to 30 days post-hospital admission, both inpatient and outpatient samples, and 528 529 excluding escalation samples). For Visit 1 analyses, we used linear modeling with age as a 530 continuous variable and controlled for sex and baseline respiratory severity. Severity was assessed using a previously described 7-point severity ordinal scale (OS) based on degree of 531 respiratory illness at the time of sampling². 532

In the longitudinal analyses, we used age quintiles ([18,46], [47,54], [55,62], [63,70] and 533 [71,96]), and controlled for sex and disease severity trajectory group (TG), a previously defined 534 metric of COVID-19 severity over time. Clinical trajectory groups were previously identified and 535 assigned to all participants in this study². For longitudinal analysis of SARS-CoV-2 nasal viral load 536 537 and serum anti-Spike IgG, we used generalized additive models with mixed effects from the package gamm4 (v0.2.6) to evaluate the effects of age while controlling for sex and TG. 538 539 Generalized additive modeling was preferred for these features due to their non-linear trajectories as previously reported. For all other data types, we used linear mixed effects models from the 540 541 package Ime4 (v1.1.25). P values in all analyses were adjusted with Benjamini-Hochberg correction. 542

543

28

544 Analysis of nasal metagenomics data

545 Taxonomic alignments from nasal metagenomics data were obtained from raw fastq files using the CZ-ID pipeline⁴⁹, which first removes human sequences via subtractive alignment 546 against human genome build 38, followed by quality and complexity filtering. Subsequently, 547 reference-based taxonomic alignment at both the nucleotide and amino acid levels against 548 sequences in the National Center for Biotechnology Information (NCBI) nucleotide (NT) and non-549 redundant (NR) databases, respectively, is carried out, followed by assembly of the reads 550 matching each taxon. Taxa were aggregated to the genus level for analyses. For all analyses 551 552 using SARS-CoV-2 viral load, log transformation of total reads per million (rpM) aligned to the 553 Beta-coronavirus genus was used.

554

555 Analysis of SARS-CoV-2 antibody titers

556 Antibody levels against the recombinant SARS-CoV-2 spike protein receptor-binding 557 domain (RBD) were measured using a research-grade enzyme-linked immunosorbent assay 558 (ELISA) as described³⁰. The optical density (OD) was measured and the area under the curve 559 was calculated, considering 0.15 OD as the cutoff.

560 Longitudinal analysis of SARS-CoV-2 viral load was performed using the gamm4 function 561 from the gamm4 package (v0.2.6), using the following formula:

562 viral_load ~ s(event_date,bs="cr") + s(event_date,bs="cr",by=age_group) + age_group + 563 trajectory_group + sex

with random effects (1|site/pid). In the formula, viral_load is the log-transformed rpM counts of SARS-CoV-2 as measured by nasal metatranscriptomics, event_date was the number of days post hospitalization, age_group was the participant's age quintile ([18,46], [47,54], [55,62], [63,70], [71,96]), TG was the participant's trajectory group, site was the participant's enrolment site and pid was the participant ID.

569

570 Analysis of PBMC and nasal RNA-seq data

571 PBMC and nasal RNA-seq libraries were sequenced on a NovaSeq 6000 (Illumina) at 100 572 bp paired-end read length. The sequencing data was aligned using STAR aligner v2.4.2a and 573 v.2.4.3⁵⁰ and GRCh38 reference genome (Ensembl releases 91 and 100). Gene count tables 574 were generated using htseq-count v0.4.1 and v0.4.2⁵¹.

For all RNA-seq analyses, we retained protein-coding genes that had a minimum of 10 575 counts in at least 20% of the samples. We normalized the gene counts using the voom function 576 (normalize.method = "quantile") from the limma package $v3.46.0^{52}$. fitted a linear model for the 577 578 gene expression with ImFit function (default settings), calculated the empirical Bayes statistics with ebayes function (default settings), and calculated the P values for differential expression with 579 Benjamini-Hochberg multiple comparison correction. For Visit 1 analyses, we controlled for sex 580 and severity OS at Visit 1, as well as log-transformed viral load in certain analyses when indicated. 581 582 In silico prediction of upstream cytokine activation was performed with Qiagen's Ingenuity Pathway Analysis software v01-21-03 (using default settings). 583

For the Visit 1 severity analysis, we defined mild/moderate participants as having baseline 584 respiratory disease severity (OS) 3-4, and severe participants as having baseline OS 5-6, and 585 586 limited to the youngest and oldest age quintiles. First, we normalized the gene counts with the voom function (normalize.method = "quantile"), and fitted a linear model for the gene expression 587 using the ImFit function and the formula $\sim 0 + age$ severity + sex, where age severity is the 588 combined categorical variable of participants' ages (young, ≤ 46 years old, or old, ≥ 71 years old) 589 590 and disease severity (mild or severe). With this parameterization, the age severity variable has 4 levels: young mild, young severe, old mild, and old severe. To assess differences between 591 severe and mild disease among young and old participants, we used the contrasts fit function on 592 593 the contrasts [young severe - young mild) and [old severe - old mild), respectively. Finally, we 594 calculated the empirical Bayes statistics on the two contrasts with the ebayes function (default

595 settings), and calculated the P values for differential expression with Benjamini-Hochberg 596 correction.

For the longitudinal analysis, we restricted to hospitalized and outpatient samples that were collected up to 30 days post hospitalization, excluding samples collected during care escalation. We retained protein-coding genes with at least 10 counts in at least 20% of samples. Next, we normalized the gene counts using the voom function without adding any covariates, and modelled the normalized gene expression using linear mixed effects (LME) model with the Imer function from the Ime4 package v1.1.25. Our LME model's formula was: gene_i ~ event_date + age_group + event_date:age_group + sex + TG + (1|pid)

604 (1)

605 where gene_i was the normalized expression of gene i.

To calculate the P value of the interaction term between event_date and age_group, we used the anova function (test = "LRT") to perform a likelihood ratio test between the model (1) above and the null model:

609 gene_i ~ event date + age group + sex + TG + (1|pid)

610 (2)

The P values from the likelihood ratio tests were then adjusted with Benjamini-Hochberg correction.

Significant genes from the longitudinal analysis of PBMC RNA-seq data were clustered with the pheatmap package v1.0.12, using the Euclidean distance metric and the Ward's linkage (clustering_method = "ward.D2"). The TCR signaling genes and inflammatory genes were obtained from the corresponding Reactome and Hallmark pathways, respectively.

617

618 Analysis of CyTOF data

Blood samples were quantified on the Fluidigm Helios mass cytometer, and the cell types were annotated using an automated annotation pipeline³⁰. Prior to analysis, we removed cells

identified as multiplets, debris, and those that were not identifiable with high confidence. Next, because neutrophils (CD16^{hi}) were much more abundant than the other cell types (median 60% of all detected cells), they were also removed. Then, we normalized the cell type abundance for each participant by calculating the percentage of each cell type, adding a pseudocount of 1 to avoid taking the logarithm of zeros (the pseudocount is added even if the percentage is higher than zero), and computing its centered log ratio (CLR):

627
$$CLR(X'_i) = \log\left(\frac{X'_i}{g(X'_i)}\right)$$

628 where log is the natural logarithm, and X_i is the percentage of the cell type i:

$$K_i' = \frac{X_i}{\sum X_i} \times 100 + 1$$

630 where X_i is the number of cells of cell type i in a participant.

For the Visit 1 analysis, we used a linear model to regress each cell type's CLRtransformed abundance on age, while controlling for sex and OS. For the longitudinal analysis, we used a linear mixed effect model to model the CLR-transformed abundance. The formulae for the full and null models are identical to equations (1) and (2).

635

636 Analysis of serum inflammatory protein (Olink) data

All samples were processed with the Olink multiplex assay inflammatory panels (Olink Proteomics), according to the manufacturer's instructions and as previously described³⁰. This inflammatory panel included 92 proteins associated with human inflammatory conditions. Target protein quantification was performed by real-time microfluidic qPCR via the Normalized Protein Expression (NPX) manager software. Data were normalized using internal controls in every sample, inter-plate control and negative controls, and correction factor and expressed as log2 scale proportional to the protein concentration. For additional quality control, we set any NPX

644 measurements below the assay's limit of detection (LOD) to zero. Next, we excluded proteins that 645 were detected in fewer than 20% of samples, resulting in 84 proteins for analysis.

For the Visit 1 analysis, we standardized the NPX values and modeled them with linear regression on participants' ages, controlling for sex and OS. For the severity analysis, we defined mild participants as baseline OS of 3-4, and severe participants as baseline OS of 5-6. We then set up two linear models, one for young participants (\leq 46 years old) and one for old participants (\geq 71 years old), to model the standardized NPX values on severity (mild or severe), while controlling for sex.

For the longitudinal analysis, we also standardized the NPX values, and used the LME models and the formulae in equations (1) and (2). Significant cytokines in the longitudinal analysis were clustered with the pheatmap package v1.0.12, using the Euclidean distance metric and the complete linkage. P values in all cytokine analyses were adjusted with Benjamini-Hochberg correction.

657

Analysis of anti-IFN-α antibody presence and correlation with interferon-related gene expression

Samples were screened for anti-type I IFN autoAbs in a multiplex, particle-based assay 660 as previously described³⁰. Participant samples with a fluorescence intensity > 3 standard 661 662 deviations above a mean of 1099 healthy controls at the earliest timepoint received were 663 considered positive for anti-IFN Abs (> 1310 FI for IFN- α). To assess whether presence of anti-IFN- α Abs correlated with changes in IFN-related gene expression, we assessed expression of 664 genes present in the REACTOME pathway "interferon alpha beta signaling" obtained from gsea-665 msigdb.org. All genes were assessed by linear regression using the formula Im(exp ~ anti IFNa 666 + age + sex + viral load), where exp was the normalized gene expression from PBMC data, 667 antilFNa was a binary variable indicating presence or absence of anti-IFN- α Abs, and viral load 668

- was the log-transformed viral load measured by SARS-CoV-2 rpM from the nasal metagenomics
- data. P values were adjusted with Benjamini-Hochberg correction.
- 671

672 Integrated analysis of serum cytokine, PBMC RNA-seq and nasal RNA-seq data

To integrate the serum cytokines/chemokines with the PBMC and nasal transcriptomic data, ligand/receptor pairs were retrieved from Omnipath, a database of known protein-protein interactions, using the R package OmnipathR to identify receptors and protein associates for ligands in the serum OLINK. The change per year of age was graphed for significant ageassociated ligands in the serum OLINK and their respective receptors/interactive proteins for both transcriptomics using the R package ComplexHeatmap.

679

680 List of Supplementary Materials:

Supplementary Table 1. Clinical and demographic characteristics of the cohort at baseline (Visit1).

- Supplementary Figure 1. Comparison of viral load as measured by nasal swab qPCR and nasal
 swab RNA-seq (metatranscriptomics).
- 685 Supplementary Figure 2. Time since symptom onset across age groups at Visit 1.
- 686 Supplementary Figure 3. Visit 1 analysis and longitudinal analysis of IgG levels.
- 687 Supplementary Figure 4. Visit 1 analysis of CyTOF data while controlling for viral load.

688 Supplementary Figure 5. Comparison of PBMC RNA-seq data from this study to healthy control

- 689 datasets, with differential gene expression analyses performed using age as a continuous 690 variable.
- 691 Supplementary Figure 6. Plots of the dynamics of 6 example genes in PBMC samples.
- 692 Supplementary Figure 7. Effect of SARS-CoV-2 viral load on age-cytokine relationship at Visit 1,
- and the dynamics of 4 example cytokines.
- 694 Supplementary Figure 8. Bacterial load (reads per million, rpM) versus age quintiles.

- 695 Supplementary Figure 9. Aging and COVID-19 severity, analyses controlled for viral load.
- 696 Supplementary Figure 10. Expression of interferon-related genes in patients with or without anti-
- 697 IFN- α antibodies at Visit 1.
- 698 Supplementary Figure 11. Network analysis of the top 10 significant serum proteins and their
- 699 receptors and downstream signaling.
- Supplementary Table 2. Prevalence of viral cases by age quintile over time in the nasal virome.
- 701
- 702 CONSORTIA
- 703 ***The IMPACC Network**
- National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda,
- MD 20814, USA: Patrice M. Becker, Alison D. Augustine, Steven M. Holland, Lindsey B. Rosen,
- 706 Serena Lee, Tatyana Vaysman
- 707 Clinical and Data Coordinating Center (CDCC) Precision Vaccines Program, Boston
- 708 Children's Hospital, Boston, MA 02115, USA: Al Ozonoff, Joann Diray-Arce, Jing Chen, Alvin
- Kho, Carly E. Milliren, Annmarie Hoch, Ana C. Chang, Kerry McEnaney, Brenda Barton, Claudia
- Lentucci, Maimouna Murphy, Mehmet Saluvan, Tanzia Shaheen, Shanshan Liu, Caitlin Syphurs,
- 711 Marisa Albert, Arash Nemati Hayati, Robert Bryant, James Abraham
- 712 Benaroya Research Institute, University of Washington, Seattle, WA 98101, USA: Matthew
- C. Altman, Naresh Doni Jayavelu, Scott Presnell, Bernard Kohr, Azlann Arnett
- La Jolla Institute for Immunology, La Jolla, CA 92037, USA: Bjoern Peters, Randi Vita, Kerstin
- 715 Westendorf
- 716 Knocean Inc. Toronto, ON M6P 2T3, Canada: James A. Overton
- 717 Precision Vaccines Program, Boston Children's Hospital, Harvard Medical School, Boston,
- 718 **MA 02115, USA:** Ofer Levy, Hanno Steen, Patrick van Zalm, Benoit Fatou, Kinga Smolen, Arthur
- 719 Viode, Simon van Haren, Meenakshi Jha

720 Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA: Lindsey

- 721 R. Baden, Kevin Mendez, Jessica Lasky-Su, Alexandra Tong, Rebecca Rooks
- 722 Metabolon Inc, Morrisville, NC 27560, USA: Scott R. Hutton, Greg Michelotti, Kari Wong
- 723 Case Western Reserve University and University Hospitals of Cleveland, Cleveland, OH
- 44106, USA: Rafick-Pierre Sekaly, Slim Fourati, Grace A. McComsey, Paul Harris, Scott Sieg,
- 725 Susan Pereira Ribeiro
- 726 Drexel University, Tower Health Hospital, Philadelphia, PA 19104, USA: Charles B. Cairns,
- 727 Elias K. Haddad, Michele A. Kutzler, Mariana Bernui, Gina Cusimano, Jennifer Connors, Kyra
- 728 Woloszczuk, David Joyner, Carolyn Edwards, Edward Lin, Nataliya Melnyk, Debra L. Powell,
- James N. Kim, I. Michael Goonewardene, Brent Simmons, Cecilia M. Smith, Mark Martens, Brett
- 730 Croen, Nicholas C. Semenza, Mathew R. Bell, Sara Furukawa, Renee McLin, George P Tegos,
- 731 Brandon Rogowski, Nathan Mege, Kristen Ulring
- 732 MyOwnMed Inc., Bethesda, MD 20817, USA: Vicki Seyfert-Margolis
- 733 Emory School of Medicine, Atlanta, GA 30322, USA: Nadine Rouphael, Steven E. Bosinger,
- Arun K. Boddapati, Greg K. Tharp, Kathryn L. Pellegrini, Brandi Johnson, Bernadine Panganiban,
- 735 Christopher Huerta, Evan J. Anderson, Hady Samaha, Jonathan Sevransky, Laurel Bristow,
- 736 Elizabeth Beagle, David Cowan, Sydney Hamilton, Thomas Hodder
- 737 Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA: Ana Fernandez-Sesma,
- 738 Viviana Simon, Florian Krammer, Harm Van Bakel, Seunghee Kim-schulze, Ana Silvia Gonzalez-
- Reiche, Jingjing Qi, Brian Lee, Juan Manuel Carreño, Gagandeep Singh, Ariel Raskin, Johnstone
- Tcheou, Zain Khalil, Adriana van de Guchte, Keith Farrugia, Zenab Khan, Geoffrey Kelly, Komal
- 741 Srivastava, Lily Eaker, Maria Carolina Bermúdez González, Lubbertus C.F. Mulder, Katherine
- 742 Beach
- 743 Immunai Inc. New York, NY 10016, USA: Adeeb Rahman
- 744 Oregon Health Sciences University, Portland, OR 97239, USA: William B. Messer, Catherine
- L. Hough, Sarah Siegel, Peter Sullivan, Zhengchun Lu

746 Stanford University School of Medicine, Palo Alto, CA 94305, USA: Holden Maecker, Bali

- 747 Pulendran, R. Kari C. Nadeau, Yael Rosenberg-Hasson, Michael Leipold, Natalia Sigal, Angela
- Rogers, Andrea Fernandez, Monali Manohar, Evan Do, Iris Chang

749 David Geffen School of Medicine at the University of California Los Angeles, Los Angeles

750 CA 90095, USA: Elaine F. Reed, Joanna Schaenman, Ramin Salehi-Rad, Adreanne M. Rivera,

751 Harry C. Pickering, Subha Sen, David Elashoff, Dawn C. Ward

752 University of California San Francisco, San Francisco, CA 94115, USA: David J. Erle,

753 Carolyn S. Calfee, Carolyn M. Hendrickson, Kirsten N. Kangelaris, Viet Nguyen, Deanna Lee,

754 Suzanna Chak, Rajani Ghale, Ana Gonzalez, Alejandra Jauregui, Carolyn Leroux, Luz Torres

755 Altamirano, Ahmad Sadeed Rashid, Andrew Willmore, Prescott G. Woodruff, Matthew F.

- 756 Krummel, Sidney Carrillo, Alyssa Ward, Charles R. Langelier, Ravi Patel, Michael Wilson, Ravi
- 757 Dandekar, Bonny Alvarenga, Jayant Rajan, Walter Eckalbar, Andrew W. Schroeder, Gabriela K.
- 758 Fragiadakis, Alexandra Tsitsiklis, Eran Mick, Yanedth Sanchez Guerrero, Rajani Ghale, Christina
- 759 Love, Lenka Maliskova, Michael Adkisson

760 Yale School of Medicine, New Haven, CT 06510, USA: David A. Hafler, Ruth R. Montgomery,

761 Albert C. Shaw, Steven H. Kleinstein, Jeremy Gygi, Shrikant Pawar, Anna Konstorum, Ernie

Chen, Chris Cotsapas, Xiaomei Wang, Leqi Xu, Charles Dela Cruz, Akiko Iwasaki, Subhasis

763 Mohanty, Allison Nelson, Yujiao Zhao, Shelli Farhadian, Hiromitsu Asashima

Yale School of Public Health, New Haven, CT 06510, USA: Denise Esserman, Leying Guan,

Anderson Brito, Jessica Rothman, Nathan Grubaugh, Albert I. Ko

766 Baylor College of Medicine and the Center for Translational Research on Inflammatory

Diseases, Houston, TX 77030, USA: David B. Corry, Farrah Kheradmand, Li-Zhen Song, Ebony
 Nelson

769 Oklahoma University Health Sciences Center, Oklahoma City, OK 73104, USA: Jordan P.

770 Metcalf, Nelson I Agudelo Higuita, Lauren Sinko, J. Leland Booth

- 771 University of Arizona, Tucson AZ 85721, USA: Monica Kraft, Chris Bime, Jarrod Mosier, Heidi
- 772 Erickson, Ron Schunk, Hiroki Kimura, Michelle Conway
- 773 University of Florida, Gainesville, FL 32611, USA: Mark A. Atkinson, Scott C. Brakenridge,
- 774 Ricardo F. Ungaro, Brittany Roth Manning,
- 775 University of Florida, Jacksonville, FL 32218, USA: Jordan Oberhaus, Faheem W. Guirgis,
- 776 University of South Florida, Tampa FL 33620, USA: Brittney Borresen, Matthew L. Anderson
- 777 University of Texas, Austin, TX 78712, USA: Lauren I. R. Ehrlich, Esther Melamed, Cole
- 778 Maguire, Justin F. Rousseau, Kerin C. Hurley, Janelle N. Geltman, Nadia Siles, Jacob E. Rogers

779

780 **References and Notes:**

- O'Driscoll, M. *et al.* Age-specific mortality and immunity patterns of SARS-CoV-2. *Nature* 590, 140–145 (2021).
- Ozonoff, A. *et al.* Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: Results from the IMPACC study. *EBioMedicine* **83**, 104208 (2022).
- Wu, C. *et al.* Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern. Med.* (2020) doi:10.1001/jamainternmed.2020.0994.
- 4. United States Centers for Disease Control and Prevention. Risk for COVID-19 Infection, Hospitalization, and Death By Age Group. *Risk for COVID-19 Infection, Hospitalization, and Death By Age Group* https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigationsdiscovery/hospitalization-death-by-age.html (2022).
- 792 5. NABEC/UKBEC Consortium *et al.* The transcriptional landscape of age in human peripheral
 793 blood. *Nat. Commun.* 6, 8570 (2015).
- Sayed, N. *et al.* An inflammatory aging clock (iAge) based on deep learning tracks
 multimorbidity, immunosenescence, frailty and cardiovascular aging. *Nat. Aging* 1, 598–615
 (2021).
- 797 7. Bartleson, J. M. *et al.* SARS-CoV-2, COVID-19 and the aging immune system. *Nat. Aging* 1, 769–782 (2021).
- 8. Hagan, T. *et al.* Transcriptional atlas of the human immune response to 13 vaccines reveals
 a common predictor of vaccine-induced antibody responses. *Nat. Immunol.* (2022)
 doi:10.1038/s41590-022-01328-6.
- 9. Parry, H. *et al.* Extended interval BNT162b2 vaccination enhances peak antibody
 generation. *Npj Vaccines* **7**, 14 (2022).
- 804 10. Saadat, S. *et al.* Binding and Neutralization Antibody Titers After a Single Vaccine Dose in
 805 Health Care Workers Previously Infected With SARS-CoV-2. *JAMA* 325, 1467 (2021).
- Filardi, B. A. *et al.* Age-dependent impairment in antibody responses elicited by a
 homologous CoronaVac booster dose. *Sci. Transl. Med.* 15, eade6023 (2023).
- 12. Lewis, S. A. *et al.* Differential dynamics of peripheral immune responses to acute SARS CoV-2 infection in older adults. *Nat. Aging* 1, 1038–1052 (2021).
- Shaw, A. C. *et al.* Dysregulation of human Toll-like receptor function in aging. *Ageing Res. Rev.* **10**, 346–353 (2011).
- 14. Kollmann, T. R., Levy, O., Montgomery, R. R. & Goriely, S. Innate Immune Function by Tolllike Receptors: Distinct Responses in Newborns and the Elderly. *Immunity* **37**, 771–783
 (2012).
- 815 15. Connors, J. *et al.* Aging alters antiviral signaling pathways resulting in functional impairment
 816 in innate immunity in response to pattern recognition receptor agonists. *GeroScience* 44,
 817 2555–2572 (2022).
- 818 16. Metcalf, T. U. *et al.* Human Monocyte Subsets Are Transcriptionally and Functionally Altered
 819 in Aging in Response to Pattern Recognition Receptor Agonists. *J. Immunol. Baltim. Md*820 1950 199, 1405–1417 (2017).
- Mick, E. *et al.* Upper airway gene expression shows a more robust adaptive immune
 response to SARS-CoV-2 in children. *Nat. Commun.* 13, 3937 (2022).
- 18. Loske, J. *et al.* Pre-activated antiviral innate immunity in the upper airways controls early
 SARS-CoV-2 infection in children. *Nat. Biotechnol.* 40, 319–324 (2022).
- 19. Bastard, P. *et al.* Autoantibodies against type I IFNs in patients with life-threatening COVID19. Science **370**, eabd4585 (2020).
- 20. van der Wijst, M. G. P. *et al.* Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. *Sci. Transl. Med.* **13**, eabh2624 (2021).

- 21. Langelier, C. *et al.* Integrating host response and unbiased microbe detection for lower
- respiratory tract infection diagnosis in critically ill adults. *Proc. Natl. Acad. Sci.* 201809700
 (2018) doi:10.1073/pnas.1809700115.
- Kalantar, K. L. *et al.* Integrated host-microbe plasma metagenomics for sepsis diagnosis in
 a prospective cohort of critically ill adults. *Nat. Microbiol.* (2022) doi:10.1038/s41564-02201237-2.
- 23. IMPACC Manuscript Writing Team & IMPACC Network Steering Committee.
 Immunophenotyping assessment in a COVID-19 cohort (IMPACC): A prospective
 longitudinal study. *Sci. Immunol.* 6, eabf3733 (2021).
- 838 24. Bajaj, V. *et al.* Aging, Immunity, and COVID-19: How Age Influences the Host Immune
 839 Response to Coronavirus Infections? *Front. Physiol.* 11, 571416 (2021).
- 25. Zheng, Y. *et al.* A human circulating immune cell landscape in aging and COVID-19. *Protein Cell* **11**, 740–770 (2020).
- 842 26. Mick, E. *et al.* Upper airway gene expression reveals suppressed immune responses to
 843 SARS-CoV-2 compared with other respiratory viruses. *Nat. Commun.* **11**, (2020).
- 27. Ogasawara, N. *et al.* Role of RANK-L as a potential inducer of ILC2-mediated type 2
 inflammation in chronic rhinosinusitis with nasal polyps. *Mucosal Immunol.* 13, 86–95
 (2020).
- 28. He, M. *et al.* An Acetylation Switch of the NLRP3 Inflammasome Regulates AgingAssociated Chronic Inflammation and Insulin Resistance. *Cell Metab.* **31**, 580-591.e5
 (2020).
- 29. Sarma, A. *et al.* Tracheal aspirate RNA sequencing identifies distinct immunological features of COVID-19 ARDS. *Nat. Commun.* **12**, 5152 (2021).
- 30. Arce, Joann et al. Multi-omic longitudinal study reveals immune correlates of clinical course among hospitalized COVID-19 patients. *Cell Rep. Med.* (2023).
- 31. Blanco-Melo, D. *et al.* Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. *Cell* **181**, 1036-1045.e9 (2020).
- 32. Cheng, J. W. *et al.* The role of CXCL12 and CCL7 chemokines in immune regulation, embryonic development, and tissue regeneration. *Cytokine* **69**, 277–283 (2014).
- 33. Meijer, B., Gearry, R. B. & Day, A. S. The Role of S100A12 as a Systemic Marker of Inflammation. *Int. J. Inflamm.* **2012**, 1–6 (2012).
- 34. Gorrell, M. D., Gysbers, V. & McCaughan, G. W. CD26: a multifunctional integral membrane
 and secreted protein of activated lymphocytes. *Scand. J. Immunol.* 54, 249–264 (2001).
- 35. Abbas, A. K., Lichtman, A. H., Pillai, S., Baker, D. L. & Baker, A. Cellular and molecular
 immunology. (Elsevier, 2018).
- 36. Galbraith, M. D. *et al.* Specialized interferon action in COVID-19. *Proc. Natl. Acad. Sci.* **119**, e2116730119 (2022).
- 37. Weigang, S. *et al.* Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID 19 patient as a source of immune escape variants. *Nat. Commun.* **12**, 6405 (2021).
- 38. Scherer, E. M. *et al.* SARS-CoV-2 Evolution and Immune Escape in Immunocompromised
 Patients. *N. Engl. J. Med.* 386, 2436–2438 (2022).
- 39. Sabbaghi, A. *et al.* Role of γδ T cells in controlling viral infections with a focus on influenza
 virus: implications for designing novel therapeutic approaches. *Virol. J.* **17**, 174 (2020).
- 40. Colonna-Romano, G. *et al.* Gamma/delta T lymphocytes are affected in the elderly. *Exp. Gerontol.* 37, 205–211 (2002).
- 41. Varchetta, S. *et al.* Unique immunological profile in patients with COVID-19. *Cell. Mol. Immunol.* 18, 604–612 (2021).
- 42. Yoo, J.-S. *et al.* SARS-CoV-2 inhibits induction of the MHC class I pathway by targeting the STAT1-IRF1-NLRC5 axis. *Nat. Commun.* **12**, 6602 (2021).
- 43. Schnittman, S. R. & Hunt, P. W. Clinical consequences of asymptomatic cytomegalovirus in treated human immunodeficency virus infection. *Curr. Opin. HIV AIDS* 16, 168–176 (2021).

880 881	44. Rasa, S. M. M. <i>et al.</i> Inflammaging is driven by upregulation of innate immune receptors and systemic interferon signaling and is ameliorated by dietary restriction. <i>Cell Rep.</i> 39 , 111017
882	(2022).
883 884	45. Mudd, P. A. <i>et al.</i> Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm. <i>Sci. Adv.</i> 6 , eabe3024 (2020)
885 885	46. Bost, P. <i>et al.</i> Host-Viral Infection Maps Reveal Signatures of Severe COVID-19 Patients.
887	47. Jung, C. <i>et al.</i> Steroid use in elderly critically ill COVID-19 patients. <i>Eur. Respir. J.</i> 58,
888	21009/9 (2021).
889	48. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-
890 891	49. Kalantar, K. L. <i>et al.</i> IDseq-An open source cloud-based pipeline and analysis service for
892	metagenomic pathogen detection and monitoring. <i>GigaScience</i> 9 , giaa111 (2020).
893	50. Dobin, A. et al. STAR. utilialast universal Riva-seq aligner. <i>Bioinformatics</i> . 29, (2015).
895	throughput sequencing data <i>Bioinformatics</i> 31 166–169 (2015)
896	52. Ritchie, M. E. <i>et al.</i> limma powers differential expression analyses for RNA-sequencing and
897	microarray studies. Nucleic Acids Res. 43, e47–e47 (2015).
898	
899	
055	
900	ACKNOWLEDGMENTS:
900 901	ACKNOWLEDGMENTS: Clinical and Data Coordinating Center: Sanya Thomas, Mitchell Cooney, Shun Rao, Sofia
900 901 902	ACKNOWLEDGMENTS: Clinical and Data Coordinating Center: Sanya Thomas, Mitchell Cooney, Shun Rao, Sofia Vignolo, Elena Morrocchi. David Geffen School of Medicine at the University of California-
900 901 902 903	ACKNOWLEDGMENTS: Clinical and Data Coordinating Center: Sanya Thomas, Mitchell Cooney, Shun Rao, Sofia Vignolo, Elena Morrocchi. David Geffen School of Medicine at the University of California- Los Angeles: Arash Naeim, Marianne Bernardo, Sarahmay Sanchez, Shannon Intluxay, Clara
900 901 902 903 904	ACKNOWLEDGMENTS: Clinical and Data Coordinating Center: Sanya Thomas, Mitchell Cooney, Shun Rao, Sofia Vignolo, Elena Morrocchi. David Geffen School of Medicine at the University of California- Los Angeles: Arash Naeim, Marianne Bernardo, Sarahmay Sanchez, Shannon Intluxay, Clara Magyar, Jenny Brook, Estefania Ramires-Sanchez, Megan Llamas, Claudia Perdomo, Clara E.
900 901 902 903 904 905	ACKNOWLEDGMENTS: Clinical and Data Coordinating Center: Sanya Thomas, Mitchell Cooney, Shun Rao, Sofia Vignolo, Elena Morrocchi. David Geffen School of Medicine at the University of California- Los Angeles: Arash Naeim, Marianne Bernardo, Sarahmay Sanchez, Shannon Intluxay, Clara Magyar, Jenny Brook, Estefania Ramires-Sanchez, Megan Llamas, Claudia Perdomo, Clara E. Magyar, Jennifer A. Fulcher, and the UCLA Center for Pathology Research Services and the
900 901 902 903 904 905 906	ACKNOWLEDGMENTS: Clinical and Data Coordinating Center: Sanya Thomas, Mitchell Cooney, Shun Rao, Sofia Vignolo, Elena Morrocchi. David Geffen School of Medicine at the University of California- Los Angeles: Arash Naeim, Marianne Bernardo, Sarahmay Sanchez, Shannon Intluxay, Clara Magyar, Jenny Brook, Estefania Ramires-Sanchez, Megan Llamas, Claudia Perdomo, Clara E. Magyar, Jennifer A. Fulcher, and the UCLA Center for Pathology Research Services and the Pathology Research Portal. Yale School of Medicine: M. Catherine Muenker, Dimitri Duvilaire,
900 901 902 903 904 905 906 907	ACKNOWLEDGMENTS: Clinical and Data Coordinating Center: Sanya Thomas, Mitchell Cooney, Shun Rao, Sofia Vignolo, Elena Morrocchi. David Geffen School of Medicine at the University of California- Los Angeles: Arash Naeim, Marianne Bernardo, Sarahmay Sanchez, Shannon Intluxay, Clara Magyar, Jenny Brook, Estefania Ramires-Sanchez, Megan Llamas, Claudia Perdomo, Clara E. Magyar, Jennifer A. Fulcher, and the UCLA Center for Pathology Research Services and the Pathology Research Portal. Yale School of Medicine: M. Catherine Muenker, Dimitri Duvilaire, Maxine Kuang, William Ruff, Khadir Raddassi, Denise Shepherd, Haowei Wang, Omkar
900 901 902 903 904 905 906 907 908	ACKNOWLEDGMENTS: Clinical and Data Coordinating Center: Sanya Thomas, Mitchell Cooney, Shun Rao, Sofia Vignolo, Elena Morrocchi. David Geffen School of Medicine at the University of California- Los Angeles: Arash Naeim, Marianne Bernardo, Sarahmay Sanchez, Shannon Intluxay, Clara Magyar, Jenny Brook, Estefania Ramires-Sanchez, Megan Llamas, Claudia Perdomo, Clara E. Magyar, Jennifer A. Fulcher, and the UCLA Center for Pathology Research Services and the Pathology Research Portal. Yale School of Medicine: M. Catherine Muenker, Dimitri Duvilaire, Maxine Kuang, William Ruff, Khadir Raddassi, Denise Shepherd, Haowei Wang, Omkar Chaudhary, Syim Salahuddin, John Fournier, Michael Rainone, Maxine Kuang.

910 Funding:

The study was funded by the United States National Institutes of Health through the following
grants: 5R01AI135803-03, 5U19AI118608-04, 5U19 AI128910-04, 5U19 AI089992,
4U19AI090023-11, 4U19AI118610-06, R01AI145835-01A1S1, 5U19AI062629-17,
5U19AI057229-17, 5U19AI125357-05, 5U19AI128913-03, 3U19AI077439-13, 5U54AI142766-

- 03, 5R01AI104870-07, 3U19AI089992-09, 3U19AI128913-03, NIH-NIAID 3U19AI1289130 and
- 916 U19AI128913-04S1 for EFR, R01 AI122220 for CC.
- 917

918 **Author contributions**:

- 919 C.R.L. conceived the idea for the project. H.V.P., A.T., C.P.M. and B.L. analyzed the data. E.K.H.,
- 920 P.M.B., S.K.S., J.C., A.H., H.P., P.v.Z., M.C.A., A.D.A., C.S.C., S.B., C.C., W.E., L.G., N.D.J.,
- 921 S.H.K., F.K., H.T.M., A.O., B.P., N.R., R.R.M., E.R., J.S., H.S., O.L. and J.D.A. provided guidance.
- H.V.P., A.T. and C.R.L. wrote the manuscript. All authors reviewed and edited the manuscript.
- 923

924 Data and code availability

- 925 Data files are available at ImmPort under accession number SDY1760 and dbGAP accession
- 926 number phs002686.v1.p1. All analysis code has been deposited at
- 927 <u>https://bitbucket.org/kleinstein/impacc-public-code/src/master/aging_manuscript/.</u>

928

Supplementary Materials

Supplementary Table 1. Clinical and demographic characteristics of the cohort at baseline (Visit 1). P values were calculated using Chi-square test for categorical variables, and Kruskal-Wallis test for continuous variables. Percentages might not sum to 100% due to rounding. The number of patients who died within 28 days is the same as the number of patients in trajectory group 5 (TG5).

Demoç	graphics	Overall population n = 1031	Age group [18,46] n = 206	Age group [47,54] n = 187	Age group [55,62] n = 216	Age group [63,70] n = 199	Age group [71,96] n = 223	P-value	
Age at enrollment (years), median (IQR) (n=1031)		59.0 (20.0)	37.0 (11.0)	51.0 (4.0)	59.0 (4.0)	67.0 (5.0)	77.0 (8.0)	<0.001	
Sox No $(9/)$	Male	639 (62%)	128 (62%)	108 (58%)	135 (63%)	123 (62%)	145 (65%)	0.68	
Sex, NO. (%)	Female	392 (38%)	78 (38%)	79 (42%)	81 (38%)	76 (38%)	78 (35%)		
	White	517 (50%)	79 (38%)	85 (45%)	95 (44%)	118 (59%)	140 (63%)		
Race No. (%)	Black/ African American	228 (22%)	49 (24%)	47 (25%)	53 (25%)	35 (18%)	44 (20%)	0.002	
Race, NO. (70)	Asian	40 (4%)	12 (6%)	6 (3%)	6 (3%)	9 (5%)	7 (3%)		
	Other/Declined/ Unknown	246 (24%)	66 (32%)	49 (26%)	62 (29%)	37 (19%)	32 (14.3%)		
	Non-Hispanic	670 (65%)	114 (55%)	120 (64%)	119 (55%)	137 (69%)	180 (81%)		
Ethnicity, No. (%)	Hispanic	319 (31%)	82 (40%)	63 (34%)	83 (38%)	57 (29%)	34 (15%)	<0.001	
	Unknown	42 (4%)	10 (5%)	4 (2%)	14 (6%)	5 (3%)	9 (4%)		
	None	65 (6%)	23 (11%)	13 (7%)	11 (5%)	10 (5%)	8 (4%)		
	Hypertension	592 (57%)	57 (28%)	96 (51%)	134 (62%)	141 (71%)	164 (74%)	<0.001	
	Diabetes	384 (37%)	45 (22%)	67 (36%)	90 (42%)	95 (48%)	87 (39%)	<0.001	
	Chronic lung disease	208 (20%)	14 (7%)	22 (12%)	43 (20%)	54 (27%)	75 (34%)	<0.001	
	Asthma	149 (14%)	34 (17%)	30 (16%)	28 (13%)	36 (18%)	21 (9%)	0.085	
	Chronic cardiac disease	282 (27%)	18 (9%)	38 (20%)	55 (25%)	70 (35%)	101 (45%)	<0.001	
Comorbidities, No. (%)	Chronic kidney disease	155 (15%)	17 (8%)	22 (12%)	41 (19%)	31 (16%)	44 (20%)	0.004	
	Chronic liver disease	51 (5%)	4 (2%)	9 (5%)	14 (6%)	14 (7%)	10 (4%)	0.14	
	Chronic neurological disorder	123 (12%)	11 (5%)	13 (7%)	22 (10%)	21 (11%)	56 (25%)	<0.001	
	Organ Transplantation	47 (5%)	7 (3%)	10 (5%)	16 (7%)	13 (7%)	1 (0%)	0.004	
	HIV/AIDS	13 (1%)	3 (1%)	3 (2%)	6 (3%)	1 (1%)	0 (0%)	0.092	
	Malignancy	101 (10%)	9 (4%)	6 (3%)	17 (8%)	25 (13%)	44 (20%)	<0.001	
	Underweight	12 (1%)	3 (1%)	1 (1%)	1 (0%)	4 (2%)	3 (1%)		
RMI Cotogon (in	Normal weight	145 (14%)	19 (9%)	17 (9%)	19 (9%)	27 (14%)	63 (28%))	
Kg/m2, No. (%)	Overweight (25.1- 29.9)	265 (26%)	41 (20%)	43 (23%)	58 (27%)	52 (26%)	71 (32%)	<0.001	
	Class 1-2 Obesity (30-39.9)	424 (41%)	82 (40%)	84 (45%)	100 (46%)	85 (43%)	73 (33%)		

			1	1		1	1		
	Class 3 Obesity (40+)	147 (14%)	44 (21%)	38 (20%)	31 (14%)	23 (12%)	11 (5%)		
	Missing		17 (8%)	4 (2%)	7 (3%)	8 (4%)	2 (1%)		
Length of hospital stay (days), median (IQR) (n=890)		6.0 (8.0)	5.0 (5.0)	5.5 (6.5)	6.0 (7.0)	7.0 (8.0)	8.0 (11.0)	<0.001	
At baseline visit (V1)								
7-point respiratory	Mechanically ventilated or ECMO (OS=6)	126 (12%)	19 (9%)	27 (14%)	31 (14%)	25 (13%)	24 (11%)		
	Non-invasive ventilation or high flow O2 (OS=5)	235 (23%)	32 (16%)	30 (16%)	52 (24%)	63 (32%)	58 (26%)	0.002	
No. (%)	Supplemental oxygen (not high flow) (OS=4)	443 (43%)	92 (45%)	82 (44%)	91 (42%)	78 (39%)	100 (45%)	0.002	
	None (OS=3)		63 (31%)	47 (25%)	41 (19%)	33 (17%)	41 (18%)		
	Missing	2 (0%)	0 (0%)	1 (1%)	1 (0%)	0 (0%)	0 (0%)		
	235 or lower	246 (24%)	29 (14%)	45 (24%)	49 (23%)	64 (32%)	59 (26%)		
SpO2/FiO2 ratio	236-315	170 (16%)	32 (16%)	26 (14%)	43 (20%)	36 (18%)	33 (15%)		
category, No. (%)	315 or higher	566 (55%)	137 (67%)	108 (58%)	113 (52%)	93 (47%)	115 (52%)	0.002	
	Missing	49 (5%)	8 (4%)	8 (4%)	11 (5%)	6 (3%)	16 (7%)		
Lymphopenia, No. (%)	<500/microliter	132 (13%)	13 (6%)	19 (10%)	32 (15%)	28 (14%)	40 (18%)	0.004	
Thrombocytopenia, No. (%)	<100,000/microliter	53 (5%)	3 (1%)	8 (4%)	13 (6%)	15 (8%)	14 (6%)	0.054	
D-dimer, No. (%)	>0.5 mg/L	542 (53%)	91 (44%)	83 (44%)	126 (58%)	108 (54%)	134 (60%)	<0.001	
Creatinine, No. (%)	>=1.5 mg/dL	169 (16%)	18 (9%)	25 (13%)	43 (20%)	31 (16%)	52 (23%)	<0.001	
CRP, No. (%)	>=10 mg/L	446 (43%)	71 (34%)	88 (47%)	99 (46%)	95 (48%)	93 (42%)	0.04	
Across all visits (V1	-V6)								
	TG1	217 (21%)	60 (29%)	44 (24%)	41 (19%)	38 (19%)	34 (15%)		
	TG2	270 (26%)	71 (34%)	57 (30%)	53 (25%)	45 (23%)	44 (20%)		
IMPACC trajectory	TG3	251 (24%)	52 (25%)	44 (24%)	56 (26%)	43 (22%)	56 (25%)	<0.001	
group, No. (70)	TG4	191 (19%)	20 (10%)	33 (18%)	44 (20%)	51 (26%)	43 (19%)		
	TG5	102 (10%)	3 (1%)	9 (5%)	22 (10%)	22 (11%)	46 (21%)		
28-day mortality,	Yes	102 (10%)	3 (1%)	9 (5%)	22 (10%)	22 (11%)	46 (21%)	10,004	
No. (%)	No	929 (90%)	203 (99%)	178 (95%)	194 (90%)	177 (89%)	177 (79%)	<0.001	
Treatment with	Yes	711 (69%)	124 (60%)	137 (73%)	150 (69%)	155 (78%)	145 (65%)	0.004	
steroids, No. (%)	No	320 (31%)	82 (40%)	50 (27%)	66 (31%)	44 (22%)	78 (35%)	0.001	
Treatment with	Yes	645 (63%)	122 (59%)	114 (61%)	133 (62%)	137 (69%)	139 (62%)	0.00	
remdesivir, No. (%)	No	386 (37%)	84 (41%)	73 (39%)	83 (38%)	62 (31%)	84 (38%)	0.33	



Supplementary Figure 1. Comparison of viral load as measured by nasal swab qPCR and nasal swab RNA-seq (metatranscriptomics). The Pearson's correlation coefficient and its P value are shown below each panel.



Supplementary Figure 2. Time since symptom onset across age groups at Visit 1. Data is available for a subset of patients (n=796 of 963 Visit 1 samples). Two outliers with >40 days since symptom onset are excluded from the plot. P value is calculated by one-way ANOVA test.



Supplementary Figure 3. Visit 1 analysis and longitudinal analysis of IgG levels. (a) RBD IgG at visit 1 in each age group. P-value determined by likelihood ratio test. (b) RBD IgG levels, as measured by area under the curve (AUC, see methods), over time in each age group. P-value determined by a generalized additive mixed model. Values plotted represent the area under the curve of the optical density (OD).



Supplementary Figure 4. Visit 1 analysis of CyTOF data while controlling for viral load. Bar plot highlighting cell types that are significantly associated with age (P < 0.05, calculated with linear regression and Benjamini-Hochberg correction). Analogous to the analyses in Figure 3b, but controlled for viral load.



Supplementary Figure 5. Comparison of PBMC RNA-seq data from this study to healthy control datasets⁵, with differential gene expression analyses performed using age as a continuous variable. (a, b) Venn diagrams of the Reactome pathways that are (a) upregulated and (b) downregulated with age. The numbers in the left circles indicate the number of pathways that are up- or down-regulated with age in the healthy control data only. The numbers in the right circles indicate the number of pathways that are up- or down-regulated with age in COVID-19 patients (our data) only. The numbers in the overlapping regions indicate the number of pathways that are up- or down-regulated with age in both healthy control and COVID-19 patients. Some examples of overlapping pathways, and of pathways that are associated with age in COVID-19 patients only are included under each Venn diagram.



Supplementary Figure 6. Plots of the dynamics of 6 example genes in PBMC samples.

Black lines indicate the regression lines for the fixed effects of the linear mixed-effects model. The grey ribbons indicate the 95% confidence intervals of the regression lines. The y-axes were truncated at 1.5× the interquartile range below the first quartile and above the third quartile. P values are calculated using the likelihood ratio test and Benjamini-Hochberg correction.



Supplementary Figure 7. Effect of SARS-CoV-2 viral load on age-cytokine relationship at Visit 1, and the dynamics of 4 example cytokines. (a) Bar plot depicting cytokines associated with age (P < 0.05, calculated with linear regression and Benjamini-Hochberg correction), while controlling for SARS-CoV-2 viral load. Supplementary Figure 6a differs from Figure 4a in that the former controlled for viral load, while the latter did not. (b) Plots demonstrating the dynamics of four cytokines TNFSF11, CXCL8, CXCL9, and IL6. Black lines indicate the regression lines for the fixed effects of the linear mixed-effects model. The grey ribbons indicate the 95% confidence intervals of the regression lines. The y-axes were truncated at 1.5× the interquartile range below the first quartile and above the third quartile. P values were calculated using the likelihood ratio test and Benjamini-Hochberg correction.



Supplementary Figure 8. Bacterial load (reads per million, rpM) versus age quintiles. Total bacterial abundance (log-transformed rpM, as measured by nasal metatranscriptomics) in each of the age quintiles. P value was calculated with one-way ANOVA test.



Supplementary Figure 9. Aging and COVID-19 severity, analyses controlled for viral load. (a, b) Dot plots depicting a) select Reactome pathways in PBMC or nasal RNA-seq data, and b) serum cytokines (olink) that were upregulated in severe patients (NIAID ordinal scales 5-6) compared to mild/moderate (NIAID ordinal scales 3-4) patients at Visit 1, stratified by age group (youngest or oldest). Analogous analyses to Fig. 7, but controlled for viral load.



Supplementary Figure 10. Expression of interferon-related genes in patients with or without anti-IFN- α antibodies at Visit 1. Normalized gene expression is plotted for the subset of samples with both PMBC RNA-seq and anti-IFN α antibody data available (n=732 visit 1 samples). All genes from the Reactome interferon alpha/beta signaling pathway with an adjusted P-value < 0.05 are included (n=18).



Supplementary Figure 11. Network analysis of the top 10 significant serum proteins and their receptors and downstream signaling. PBMC RNA-seq and serum cytokine data was integrated using Cytoscape.

Supplementary Table 2. Prevalence of viral cases by age quintile over time in the nasal virome. Adjusted P values (P adj, Benjamini-Hochberg method) are determined by ANOVA with respect to change in prevalence of virus over time within each age quintile. HHV = human herpes virus, CMV = cytomegalovirus, EBV = Epstein Barr virus, HSV = herpes simplex virus.

	Age							
Virus	Quantile	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	P adj
		0.52%	1.01%	0%	1.61%	0%	0%	
	[18,46]	(1/191)	(1/99)	(0/53)	(1/62)	(0/4)	(0/39)	1.0
		0%	0.95%	1.61%	1.79%	0%	0%	
	[47,54]	(0/175)	(1/105)	(1/62)	(1/56)	(0/17)	(0/36)	0.61
CMV		0.49%	0%	0%	0%	0%	0%	
(HHV-5)	[55,62]	(1/205)	(0/128)	(0/79)	(0/70)	(0/20)	(0/42)	1.0
		0%	1.79%	1.24%	1.49%	4.17%	3.03%	
	[63,70]	(0/190)	(2/112)	(1/81)	(1/67)	(1/24)	(1/33)	0.24
		0.47%	0%		1.27%	11.54%	6.90%	
	[71,96]	(1/212)	(0/133)	0% (0/94)	(1/79)	(3/26)	(2/29)	1.70E-03
		0%	0%	0%	0%	0%	0%	
	[18,46]	(0/191)	(0/99)	(0/53)	(0/62)	(0/4)	(0/39)	1.0
		1.14%	3.8%	1.61%	0%	0%	0%	
	[47,54]	(2/175)	(4/105)	(1/62)	(0/56)	(0/17)	(0/36)	0.71
EBV		0.49%	2.34%	2.53%	4.29%	5.0%	4.76%	
(HHV-4)	[55,62]	(1/205)	(3/128)	(2/79)	(3/70)	(1/20)	(2/42)	0.24
		1.58%	0.89%	4.94%	2.99%	8.33%	0%	
	[63,70]	(3/190)	(1/112)	(4/81)	(2/67)	(2/24)	(0/33)	0.24
		0%	1.50%	4.26%	1.27%	7.70%	3.45%	
	[71,96]	(0/212)	(2/133)	(4/94)	(1/79)	(2/26)	(1/29)	0.039
		0%	0%	0%	1.61%	0%	2.56%	
	[18,46]	(0/191)	(0/99)	(0/53)	(1/62)	(0/4)	(1/39)	0.24
		0.57%	1.9%	1.6%	5.36%	0%	5.56%	
	[47,54]	(1/175)	(2/105)	(1/62)	(3/56)	(0/17)	(2/36)	0.24
Dogiviruo		0.98%	0.78%	0%	1.43%	0%	0%	
regivirus	[55,62]	(2/205)	(1/128)	(0/79)	(1/70)	(0/20)	(0/42)	1.0
		0%	0%	0%	0%	0%	0%	
	[63,70]	(0/190)	(0/112)	(0/81)	(0/67)	(0/24)	(0/33)	1.0
		0%	0%	0%	1.27%	0%	0%	
	[71,96]	(0/212)	(0/133)	(0/94)	(1/79)	(0/26)	(0/29)	0.43
HSV		4.71%	8.08%	9.43%	3.23%	0%	2.56%	
(HHV-1/2)	[18,46]	(9/191)	(8/99)	(5/53)	(2/62)	(0/4)	(1/39)	0.71
		3.43%	5.71%	6.45%	7.14%	11.77%	5.56%	
	[47,54]	(6/175)	(6/105)	(4/62)	(4/56)	(2/17)	(2/36)	0.71
		2.44%	6.25%	8.86%	11.43%	5.0%	9.52%	
	[55,62]	(5/205)	(8/128)	(7/79)	(8/70)	(1/20)	(4/42)	0.13
		3.16%	5.36%	12.35%	13.43%	12.50%	6.06%	
	[63,70]	(6/190)	(6/112)	(10/81)	(9/67)	(3/24)	(2/33)	0.056
		2.36%	5.26%	4.26%	16.46%	30.77%	17.24%	
	[71,96]	(5/212)	(7/133)	(4/94)	(13/79)	(8/26)	(5/29)	4.50E-06